EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy

Chilam Chan, Núria Casalé Cabanes, J H Marco Jansen, Joël Guillaume, Maaike Nederend, Elsemieke M Passchier, Valentina E Gómez-Mellado, Matthias Peipp, Marianne Boes, Geert van Tetering, Jeanette H W Leusen

Cancer Immunology, Immunotherapy · 2024

DOI: 10.1007/s00262-024-03824-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Chilam Chan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Translational Immunology, University Medical Center, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Immunotherapy, Immunoglobulin A, Antibody-Dependent Cell Cytotoxicity. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: KWF Kankerbestrijding, Oncode Accelerator.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent advances in cancer immunotherapy, particularly the success of immune checkpoint inhibitors, have reignited interest in targeted monoclonal antibodies for immunotherapy. Antibody therapies aim to minimize on-target, off-tumor toxicity by targeting antigens overexpressed on tumor cells but not on healthy cells. Despite considerable efforts, some therapeutic antibodies have been linked to dose-limiting side effects. Our hypothesis suggests that the efficacy of IgG leads to a lower target expression threshold for tumor cell killing, contributing to these side effects. Earlier, therapeutic IgG antibodies were reformatted into the IgA isotype. Unlike IgG, which primarily engages Fc gamma receptors (FcγR) to induce antibody-dependent cellular cytotoxicity (ADCC) by NK cells and antibody-dependent cellular phagocytosis (ADCP) by monocytes/macrophages, IgA antibodies activate neutrophils through the Fc alpha receptor I (CD89, FcαRI). In previous studies, it appeared that IgA may require a higher target expression threshold for effective killing, and we aimed to investigate this in our current study. Moreover, we investigated how blocking the myeloid checkpoint CD47/SIRPα axis affect the target expression threshold. Using a tetracycline-inducible expression system, we regulated target expression in different cell lines. Our findings from ADCC assays indicate that IgA-mediated PMN ADCC requires a higher antigen expression level than IgG-mediated PBMC ADCC. Furthermore, blocking CD47 enhanced IgA-mediated ADCC, lowering the antigen threshold. Validated in two in vivo models, our results show that IgA significantly reduces tumor growth in high-antigen-expressing tumors without affecting low-antigen-expressing healthy tissues. This suggests IgA-based immunotherapy could potentially minimize on-target, off-tumor side effects, improving treatment efficacy and patient safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyImmunoglobulin AAntibody-Dependent Cell CytotoxicityHumansAnimalsMiceNeoplasmsCell Line, TumorKiller Cells, NaturalFemale

Stichwörter der Autor:innen

Antigen expression levelsCD47/SIRPαIgAImmunotherapyNeutrophils

Substanzen

Immunoglobulin A

Autor:innen und Institutionen

  • Center for Translational Immunology, University Medical Center, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
  • Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Division of Antibody-Based Immunotherapy, Department of Medicine II, Christian Albrechts University Kiel and University Medical Center Schleswig-Holstein, Campus Kiel, 24105, Kiel, Germany.
  • Pediatrics Department, University Medical Center, Utrecht, The Netherlands.
  • Center for Translational Immunology, University Medical Center, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands. J.H.W.Leusen@umcutrecht.nl.

Förderung

  • KWF Kankerbestrijding
  • Oncode Accelerator

Zitieren

APA

Chan, C., Cabanes, N. C., Jansen, J. H. M., Guillaume, J., Nederend, M., Passchier, E. M., Gómez-Mellado, V. E., Peipp, M., Boes, M., van Tetering, G., & Leusen, J. H. W. (2024). The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03824-0

Vancouver

Chan C, Cabanes NC, Jansen JHM, Guillaume J, Nederend M, Passchier EM, et al. The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03824-0

BibTeX
@article{Chan2024,
  author = {Chan, Chilam and Cabanes, Núria Casalé and Jansen, J H Marco and Guillaume, Joël and Nederend, Maaike and Passchier, Elsemieke M and Gómez-Mellado, Valentina E and Peipp, Matthias and Boes, Marianne and van Tetering, Geert and Leusen, Jeanette H W},
  title = {The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  doi = {10.1007/s00262-024-03824-0}
}
Kostenlos starten →